Semaglutide is a synthetically produced peptide derived structurally from the endogenous incretin hormone GLP-1 (glucagon-like peptide-1). GLP-1 is formed in the intestine and is part of the system by which the body regulates insulin release and glucose metabolism. Semaglutide is a modified analogue of the sequence GLP-1(7–37): targeted changes in the peptide backbone and a fatty acid chain attached via a linker considerably extend the stability of the molecule compared with the native hormone.
Pharmacologically, semaglutide is assigned to the class of GLP-1 receptor agonists. One point matters for classification: the active substance semaglutide is a component of approved, prescription-only medicines – these are available exclusively through pharmacies and are not the subject of this page. In the research field, semaglutide is handled separately from this, as a reference and research material for laboratory analytics and preclinical questions.
Profile
Molecule type: synthetic GLP-1 analogue with fatty acid side chain (lipidated peptide)
Number of amino acids: 31 (modified backbone based on GLP-1(7–37))
Substance class (pharmacological classification): GLP-1 receptor agonist
Research classification: reference and research material, Research Use Only (RUO)
Research context
Semaglutide is among the most intensively studied peptides in metabolic research. In basic and preclinical research the molecule is examined in connection with the GLP-1 receptor: receptor binding, signal transduction and the question of how the fatty acid modification influences albumin binding and degradation behaviour are recurring topics in the literature.
Beyond that, semaglutide serves in many laboratories as an analytical reference substance – for method development in HPLC and mass-spectrometric peptide analysis, for example, or for stability studies on lipidated peptides. The substance is also the subject of published work in cell and animal models of energy metabolism. This research is reported here in purely descriptive terms; it does not replace a regulatory assessment under medicines law and does not establish any recommendation for use.
Quality criteria for laboratory procurement
Analytical documentation is central precisely for complex modified peptides such as semaglutide. A complete COA covers HPLC purity, mass-spectrometric confirmation of the molecular mass – which here also reflects the correct fatty acid modification – and a unique batch number. Without this information, the quality of a batch cannot be assessed in the laboratory.
Semaglutide is supplied lyophilised and stored dry, cool and protected from light; long-term storage is usually in the freezer. Since lipidated peptides can react sensitively to repeated temperature changes, working with aliquots is advisable in laboratory practice.
Frequently asked questions
Is semaglutide legal as a research material?
Yes – obtaining semaglutide as a reference and research material for scientific purposes is legal. Approved finished medicinal products containing this active substance must be strictly distinguished from it: those are prescription-only and available exclusively through pharmacies. Research material must never be used in humans.
What should be checked on the COA?
Alongside the batch number and HPLC purity, mass-spectrometric identity testing is particularly important for semaglutide, because only this confirms that the complete, correctly modified molecule is present. The certificate must be unambiguously assignable to the batch supplied.
How is semaglutide stored?
The lyophilised material is kept dry, dark and cool, preferably frozen for the long term. Freeze-thaw cycles should be minimised; dividing the material into single aliquots is the usual laboratory route to securing material quality over longer project periods.
Available at Peptélia
Peptélia carries semaglutide as batch-documented research material with a certificate of analysis (COA). The available products can be found in the Semaglutide category at Peptélia.
Important notice
All substances offered by Peptélia are intended exclusively for scientific use in the laboratory (Research Use Only). They are not medicines, not food supplements and not cosmetics. Use in humans or animals, as well as any diagnostic or therapeutic use, is expressly excluded.
Distinction from approved medicines: semaglutide is the active substance of prescription medicines such as Ozempic and Wegovy. Peptélia does not distribute these medicines. The present article is purely informative and constitutes neither a procurement nor a usage guide.
For research use only. Not for use in or on the human body.
